Physician’s Weekly: PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.
August 20, 2020Although cancer is the leading cause of disease-related mortality in children, the relative rarity of pediatric cancers poses a significant challenge for developing novel therapeutics to further improve prognosis. Patient-derived xenograft (PDX) models …
Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
December 17, 2019The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both …
Innovation News Network: Innovative genomics and bioinformatics research at the Greehey Institute (Multiple Investigators)
June 18, 2019The past decade has witnessed a revolution in cancer research, largely driven by advances in high-throughput sequencing, functional genomics, and computational technologies. The affordability and technological maturity of high-throughput data generatio …
Business Wire: Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
November 4, 2015CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase ( …
Frontiers in Oncology: Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
August 26, 2015Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. …